Rapid Communication ADAM 17 Mediates Epidermal Growth Factor Receptor Transactivation and Vascular Smooth Muscle Cell Hypertrophy Induced by Angiotensin II

Background—Angiotensin II (Ang II) promotes growth of vascular smooth muscle cells (VSMCs) via epidermal growth factor (EGF) receptor (EGFR) transactivation mediated through a metalloprotease-dependent shedding of heparinbinding EGF-like growth factor (HB-EGF). However, the identity of the metalloprotease responsible for this process remains unknown. Methods and Results—To identify the metalloprotease required for Ang II-induced EGFR transactivation, primary cultured aortic VSMCs were infected with retrovirus encoding dominant negative (dn) mutant of ADAM10 or ADAM17. EGFR transactivation induced by Ang II was inhibited in VSMCs infected with dnADAM17 retrovirus but not with dnADAM10 retrovirus. However, Ang II comparably stimulated intracellular Ca elevation and JAK2 tyrosine phosphorylation in these VSMCs. In addition, dnADAM17 inhibited HB-EGF shedding induced by Ang II in A10 VSMCs expressing the AT1 receptor. Moreover, Ang II enhanced protein synthesis and cell volume in VSMCs infected with control retrovirus, but not in VSMCs infected with dnADAM17 retrovirus. Conclusion—ADAM17 activated by the AT1 receptor is responsible for EGFR transactivation and subsequent protein synthesis in VSMCs. These findings demonstrate a previously missing molecular mechanism by which Ang II promotes vascular remodeling. (Arterioscler Thromb Vasc Biol. 2006;26:e133-e137.)

[1]  P. Dempsey,et al.  ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. , 2006, American journal of physiology. Cell physiology.

[2]  H. Ueno,et al.  Angiotensin II-induced activation of p21-activated kinase 1 requires Ca2+ and protein kinase Cδ in vascular smooth muscle cells , 2005 .

[3]  R. Alexander,et al.  cAbl Tyrosine Kinase Mediates Reactive Oxygen Species– and Caveolin-Dependent AT1 Receptor Signaling in Vascular Smooth Muscle: Role in Vascular Hypertrophy , 2005, Circulation research.

[4]  S. Eguchi,et al.  Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction and structural requirement. , 2005, Current medicinal chemistry. Cardiovascular and hematological agents.

[5]  J. Rothstein,et al.  Signal-Crosstalk Between Rho/ROCK and c-Jun NH2-Terminal Kinase Mediates Migration of Vascular Smooth Muscle Cells Stimulated by Angiotensin II , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[6]  Shunqiang Li,et al.  Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach , 2005, Nature Medicine.

[7]  M. Mifune,et al.  G Protein Coupling and Second Messenger Generation Are Indispensable for Metalloprotease-dependent, Heparin-binding Epidermal Growth Factor Shedding through Angiotensin II Type-1 Receptor* , 2005, Journal of Biological Chemistry.

[8]  P. Dempsey,et al.  ADAM10 Mediates Ectodomain Shedding of the Betacellulin Precursor Activated by p-Aminophenylmercuric Acetate and Extracellular Calcium Influx* , 2005, Journal of Biological Chemistry.

[9]  A. Ullrich,et al.  Distinct ADAM Metalloproteinases Regulate G Protein-coupled Receptor-induced Cell Proliferation and Survival* , 2004, Journal of Biological Chemistry.

[10]  David C. Lee,et al.  Transactivation of Epidermal Growth Factor Receptor Mediates Catecholamine-Induced Growth of Vascular Smooth Muscle , 2004, Circulation research.

[11]  Koichiro Yoshino,et al.  ADAM Binding Protein Eve-1 Is Required for Ectodomain Shedding of Epidermal Growth Factor Receptor Ligands* , 2004, Journal of Biological Chemistry.

[12]  M. Mifune,et al.  Metalloprotease-dependent ErbB ligand shedding in mediating EGFR transactivation and vascular remodelling. , 2003, Biochemical Society transactions.

[13]  N. Matsuura,et al.  PACSIN3 Binds ADAM12/Meltrin α and Up-regulates Ectodomain Shedding of Heparin-binding Epidermal Growth Factor-like Growth Factor* , 2003, Journal of Biological Chemistry.

[14]  R. Derynck,et al.  Characterization of Growth Factor-induced Serine Phosphorylation of Tumor Necrosis Factor-α Converting Enzyme and of an Alternatively Translated Polypeptide* , 2003, The Journal of Biological Chemistry.

[15]  J. Sadoshima,et al.  Phosphorylation of Tyrosine 319 of the Angiotensin II Type 1 Receptor Mediates Angiotensin II-induced Trans-activation of the Epidermal Growth Factor Receptor* , 2003, The Journal of Biological Chemistry.

[16]  N. Dun,et al.  Urotensin‐II regulates intracellular calcium in dissociated rat spinal cord neurons , 2002, Journal of neurochemistry.

[17]  P. Seshiah,et al.  Angiotensin II Stimulation of NAD(P)H Oxidase Activity: Upstream Mediators , 2002, Circulation research.

[18]  E. Dı́az-Rodrı́guez,et al.  Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. , 2002, Molecular biology of the cell.

[19]  J. Kamei,et al.  Lysophosphatidylcholine Activates Extracellular Signal-Regulated Kinases 1/2 Through Reactive Oxygen Species in Rat Vascular Smooth Muscle Cells , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[20]  R. Hannan,et al.  Adenoviral-Directed Expression of the Type 1A Angiotensin Receptor Promotes Cardiomyocyte Hypertrophy via Transactivation of the Epidermal Growth Factor Receptor , 2002, Circulation research.

[21]  S Eguchi,et al.  Activation of MAPKs by Angiotensin II in Vascular Smooth Muscle Cells , 2001, The Journal of Biological Chemistry.

[22]  Y. Mori,et al.  Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. , 2001, Circulation research.

[23]  E. Schiffrin,et al.  Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. , 2000, Pharmacological reviews.

[24]  J. Abraham,et al.  Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. , 2000, Circulation research.

[25]  H. Kawakatsu,et al.  Calcium-dependent Epidermal Growth Factor Receptor Transactivation Mediates the Angiotensin II-induced Mitogen-activated Protein Kinase Activation in Vascular Smooth Muscle Cells* , 1998, The Journal of Biological Chemistry.

[26]  C. Blobel,et al.  ADAMs: key components in EGFR signalling and development , 2005, Nature Reviews Molecular Cell Biology.

[27]  Hiroshi Asanuma,et al.  Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy , 2002, Nature Medicine.

[28]  B. Berk,et al.  Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. , 2001, Journal of molecular and cellular cardiology.

[29]  R. Alexander,et al.  Angiotensin II signaling in vascular smooth muscle. New concepts. , 1997, Hypertension.